Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Deepak Bhatt acquired deferred share units of Bristol-Myers Squibb, convertible to common stock upon cessation of directorship or at a specified future date.

Summary

• On June 30, 2024, Deepak Bhatt, a director of Bristol-Myers Squibb, acquired 210.691 deferred share units.
• These units will convert into shares of common stock upon settlement, which occurs when Bhatt ceases to be a director or at a previously specified future date.
• The price of the deferred share units was $41.53.
• Following the transaction, Bhatt beneficially owns 10,397.463 shares, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of deferred share units by a director is a common practice and suggests alignment with the company's long-term interests. There are no explicitly negative indicators.

Positives

• The acquisition of deferred share units aligns the director's interests with the long-term performance of the company.
• Reinvestment of dividends indicates confidence in the company's future prospects.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Comparison to Industry Standards

• Director compensation packages often include deferred share units to align executive interests with shareholder value, a common practice among publicly traded companies like Pfizer (PFE) and Johnson & Johnson (JNJ).
• The vesting and settlement terms, contingent on continued service or a specified future date, are standard features in such compensation plans, similar to those used by Merck (MRK) and AbbVie (ABBV).

Stakeholder Impact

• The acquisition of deferred share units by a director can positively influence shareholder confidence by aligning management's interests with the company's performance.

Key Dates